Whether such a selective preference for Th2 autoimmunity against PLP or MOBP in the context of DRB1*1501, and Th1/Th17 autoimmunity in the context of DQB1*0602, occurs also in HLA-DR15+ MS should be examined by ex-vivo analysis the patients' responses to these myelin antigen/epitopes in the context of DRB1*1501- and DQB1*0602-associated antigen presentation. Here, HLA-DRB1 is linked to myeloid sarcoma.